Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Weight loss (change in kg weight) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review
Quality of life: FACT‐G (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Relapse: return to any drinking at end of treatment · alcohol use disorder
Summary of findings table ‐ Baclofen probably leads to lower relapse: return to any drinking at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of use % days abstinence at the end of treatment · alcohol use disorder
1 finding from 1 review
Frequency of use % of heavy drinking days at the end of treatment · alcohol use disorder
1 finding from 1 review
Amount of use drink per drinking days at the end of treatment · alcohol use disorder
1 finding from 1 review
Adverse events: number of participants with ≥ 1 adverse event at end of treatment · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in adverse events: number of participants with ≥ 1 adverse event at end… compared with placebo (high certainty).
1 finding from 1 review
Dropout · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in dropouts at end of treatment compared with placebo (high certainty).
1 finding from 1 review
Dropouts due to adverse events · alcohol use disorder
Summary of findings table ‐ Baclofen showed no clear difference in dropouts due to adverse events compared with placebo (high certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).
1 finding from 1 review
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).
1 finding from 1 review
Total hip BMD · premenopausal women (age 18−47.3 years)
1 finding from 1 review
Quality of life · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found